New combo therapy offers hope for head and neck cancer patients who can't have chemo

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eligible subjects must meet all of the following: * Age ≥18 years. * Histologically confirmed stage III-IVB (AJCC 8th edition) head and neck squamous cell carcinoma (including cancers of the oral cavity, oropharynx, hypopharynx, and larynx). * Unsuitable for surgical treatment (defined as: due to patient condition or tumor factors \[T3-4 N0-3 M0, or T1-2 N2-3 M0\] or medical reasons, surgery is not feasible; or an R0 resection is not achievable). * Suitable for definitive radiotherapy with curative intent. * At least one of the following reasons for being unsuitable for cisplatin-based chemotherapy: * Age ≥65 years and, in the investigator's judgment, unable to tolerate chemotherapy; * ECOG Performance Status \>2 (if this criterion is met, the ECOG criterion listed below may be waived); * Renal dysfunction: creatinine clearance (CrCl) \<50 mL/min (Cockcroft-Gault) (if this criterion is met, the renal function criterion listed below may be waived); * Severe tinnitus or hearing loss (requires a hearing aid or audiometry shows ≥25 dB loss at two consecutive frequencies); * Peripheral neuropathy \> Grade 1; * Inability to receive intravenous hydration (e.g., due to cardiac dysfunction) or other comorbidities, per investigator's judgment. * Provide tumor tissue, whenever possible, for EGFR testing; for oropharyngeal cancer, provide tissue for HPV/p16 testing if feasible (no need to retest if previously tested). * ECOG Performance Status 0-1 (or Karnofsky Performance Status ≥80). * At least one measurable lesion per RECIST 1.1. * Expected survival ≥6 months. * Adequate hematologic function: WBC ≥4×10\^9/L; absolute neutrophil count ≥1.5×10\^9/L; platelets ≥100×10\^9/L; hemoglobin ≥90 g/L. * Adequate renal function: serum creatinine ≤1.5×ULN or CrCl ≥60 mL/min (Cockcroft-Gault): * Female CrCl = (140 - age) × weight (kg) × 0.85 / (72 × S\_cr \[mg/dL\]) * Male CrCl = (140 - age) × weight (kg) × 1.00 / (72 × S\_cr \[mg/dL\]) * Adequate liver function: total bilirubin ≤1.5×ULN; AST ≤2.5×ULN; ALT ≤2.5×ULN. * Voluntary participation: signed written informed consent and ability to comply with visits and procedures. Exclusion Criteria: * Any of the following excludes enrollment: * Receipt of a PD-1 inhibitor, EGFR monoclonal antibody, EGFR-TKI, or anti-angiogenic agent within 4 weeks prior to enrollment. * Participation in another interventional clinical trial within 30 days prior to screening. * History of other malignancy (except cured basal cell carcinoma of the skin). * History of primary immunodeficiency. * Uncontrolled comorbid conditions (e.g., congestive heart failure, severe pulmonary disease, severe liver disease, psychiatric illness). * Known HIV infection, or active viral hepatitis or active tuberculosis. * Major surgery within 90 days before first study treatment, or planned surgery during the study. * Known allergy to nimotuzumab or its excipients. * Deemed unsuitable to participate by the investigator. * Unwilling or unable to sign informed consent. * Receipt of a live vaccine within 30 days before first dose.